Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

$315.50 +1.33 (+0.42%)

(As of 10:05 AM ET)

Madrigal Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
1

Hold
2

Buy
10

Based on 13 Wall Street analysts who have issued ratings for Madrigal Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 2 have given a hold rating, and 10 have given a buy rating for MDGL.

Consensus Price Target

$347.33
10.09% Upside

According to the 13 analysts' twelve-month price targets for Madrigal Pharmaceuticals, the average price target is $347.33. The highest price target for MDGL is $441.00, while the lowest price target for MDGL is $150.00. The average price target represents a forecasted upside of 10.09% from the current price of $315.50.

Get the Latest News and Ratings for MDGL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Madrigal Pharmaceuticals and its competitors.

MDGL Analyst Ratings Over Time

Type	Current Forecast 11/21/23 to 11/20/24	1 Month Ago 10/22/23 to 10/21/24	3 Months Ago 8/23/23 to 8/22/24	1 Year Ago 11/21/22 to 11/21/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$347.33	$343.83	$343.83	$313.09
Forecasted Upside	10.09% Upside	64.60% Upside	38.26% Upside	66.15% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

This thing would have won 534 of the 550 trades placed in the last 11 years (Ad)

Choosing what your next move will be is one of the most difficult choices investors are faced with today — especially in turbulent markets like these. But what if there was one technique that checked all these boxes? ✅ Allows traders of all stripes to target extra income week after week ✅ Won 534 of 550 trades according to our backtesting on 11-years worth of data ✅ Has maintained a shocking 97.1% through every market condition imaginable ✅ Sets up “Weekly Windfalls” every week so that it’s never trading opposite the broad market direction Well, we’re here to tell you, that strategy isn’t a pipe dream… It’s the same flagship strategy Chris Pulver just released an urgent briefing on! And your friends at Prosperity Pub have secured the video just for you. And with the very next trade dropping THIS WEEK you couldn't have better timing! While we cannot promise future returns or against losses, you have to…

While we cannot promise future returns or against losses, you have to… Check out this training ses

MDGL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MDGL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Madrigal Pharmaceuticals Stock vs. The Competition

Type	Madrigal Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.69	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	10.56% Upside	27,981.10% Upside	9.99% Upside
News Sentiment Rating	Positive News See Recent MDGL News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/20/2024	Cantor Fitzgerald 3 of 5 stars	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
11/5/2024	B. Riley 4 of 5 stars		Boost Target	Neutral ➝ Neutral	$194.00 ➝ $236.00	-28.05%
11/1/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$411.00 ➝ $441.00	+41.45%
10/23/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$375.00 ➝ $350.00	+71.91%
10/22/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$390.00 ➝ $390.00	+86.70%
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$382.00 ➝ $371.00	+54.04%
Get the Latest News and Ratings for MDGL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$405.00 ➝ $360.00	+53.79%
7/16/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Outperform ➝ Market Outperform	$381.00 ➝ $385.00	+36.85%
6/11/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$382.00	+49.87%
4/22/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform	$150.00	-29.26%
3/15/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$338.00 ➝ $377.00	+30.88%
3/15/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$349.00 ➝ $390.00	+35.40%
3/14/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$336.00	+16.65%
12/20/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$145.00 ➝ $315.00	+25.86%
12/20/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$129.00 ➝ $309.00	+31.58%
12/19/2022	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform
12/19/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$178.00 ➝ $375.00	+66.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:29 AM ET.

MDGL Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Madrigal Pharmaceuticals is $347.33, with a high forecast of $441.00 and a low forecast of $150.00.
: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MDGL shares.
: According to analysts, Madrigal Pharmaceuticals's stock has a predicted upside of 10.09% based on their 12-month stock forecasts.
: Madrigal Pharmaceuticals has been rated by research analysts at B. Riley, Cantor Fitzgerald, HC Wainwright, Oppenheimer, and UBS Group in the past 90 days.
: Analysts like Madrigal Pharmaceuticals less than other "medical" companies. The consensus rating score for Madrigal Pharmaceuticals is 2.69 while the average consensus rating score for "medical" companies is 2.80. Learn more on how MDGL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

This page (NASDAQ:MDGL) was last updated on 11/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target